31 results
8-K
EX-99.2
LIANY
LianBio
10 Nov 22
LianBio Reports Third Quarter 2022 Financial Results and Provides Corporate Update
4:16pm
-in- class drugs approved Comprehensive policies enacted to foster innovation China’s five-year plan includes innovation priorities in TAs … , with Innovation Agenda Propelling Strong Growth 4 Substantial unmet medical needs persist in China 1. GBD Global Healthdata Exchange 2019; 2. “Healthy China 2030
8-K
EX-99.2
LIANY
LianBio
11 Aug 22
LianBio Reports Second Quarter 2022 Financial Results and Provides Corporate Update
4:30pm
drugs approved Comprehensive policies enacted to foster innovation China’s five-year plan includes innovation priorities in TAs such as oncology … and CV3 Accelerated review and approval timelines of patented pharmaceuticals4 China is the Second Largest Pharmaceutical Market Today, with Innovation
8-K
EX-99.2
LIANY
LianBio
12 May 22
LianBio Reports First Quarter 2022 Financial Results and Provides Corporate Update
9:15am
Comprehensive policies enacted to foster innovation China’s five-year plan includes innovation priorities in TAs such as oncology and CV3 Accelerated review … and approval timelines of patented pharmaceuticals4 China is the Second Largest Pharmaceutical Market Today, with Innovation Agenda Propelling Strong
10-K
2021 FY
LIANY
LianBio
31 Mar 22
Annual report
8:55am
innovation and an improving reimbursement and access landscape have all increased the strategic importance of the Chinese pharmaceutical market … innovation to develop and maintain our proprietary and intellectual property position, which we generally seek to protect through contractual
8-K
EX-99.1
LIANY
LianBio
2 Mar 22
Regulation FD Disclosure
4:42pm
to foster innovation China’s five-year plan includes innovation priorities in TAs such as oncology and CV3 Accelerated review and approval timelines … of patented pharmaceuticals4 China is the Second Largest Pharmaceutical Market Today, with Innovation Agenda Propelling Strong Growth 4 Substantial unmet
10-Q/A
ji28cst64
10 Jan 22
Quarterly report (amended)
4:06pm
10-Q
5sz vo3p7wlsq5faqyj
9 Dec 21
Quarterly report
5:24pm
424B4
54tmikjbe
2 Nov 21
Prospectus supplement with pricing info
4:02pm
S-1/A
jzbx73smpdj82xwaybdc
8 Oct 21
IPO registration (amended)
5:09pm
S-1
EX-10.1
svq5o v4o5mchz
1 Oct 21
IPO registration
4:52pm
S-1
EX-10.5
wy6qsf gaq
1 Oct 21
IPO registration
4:52pm
S-1
EX-10.12
lfbjs fte9amgv00atl
1 Oct 21
IPO registration
4:52pm
S-1
EX-10.16
eh1wmy8fqc abm8xh9
1 Oct 21
IPO registration
4:52pm
S-1
EX-10.15
vfdhpj3s
1 Oct 21
IPO registration
4:52pm
S-1
EX-10.8
b3sm3sh7p3gnh
1 Oct 21
IPO registration
4:52pm
S-1
EX-4.3
u4sae0xa tghvqouj28
1 Oct 21
IPO registration
4:52pm
S-1
734a4
1 Oct 21
IPO registration
4:52pm